For de øvrige parametre blev der med kombinationsbehandlingen set følgende forbedringer: samlet respons (16, 5% versus 6, 7%); klinisk benefit ratio (42, 7% versus 27, 9%); tid til progression (4, 8 måneder versus 2, 4 måneder).
For the other parameters the improvements seen for the combination were for overall response (16.5% versus 6.7%); clinical benefit rate (42.7% versus 27.9%); time to progression (4.8 months versus 2.4 months).